Recombinant influenza hemagglutinin — Competitive Intelligence Brief

Recombinant influenza hemagglutinin (Recombinant influenza hemagglutinin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

marketed Recombinant protein vaccine Influenza hemagglutinin Immunology / Infectious Disease Biologic

Target snapshot

Recombinant influenza hemagglutinin (Recombinant influenza hemagglutinin) — Vaxine Pty Ltd. Recombinant influenza hemagglutinin stimulates the immune system to produce antibodies and cellular immunity against influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant influenza hemagglutinin TARGET	Recombinant influenza hemagglutinin	Vaxine Pty Ltd	marketed	Recombinant protein vaccine	Influenza hemagglutinin
Influenza	Influenza and COVID-19 Combination A	BioNTech	marketed	Non-Standardized Plant Allergenic Extract [EPC]	SARS-CoV-2 spike protein and influenza hemagglutinin protein
Recombinant influenza vaccines	Recombinant influenza vaccines	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Vaccine	Influenza hemagglutinin (HA) and neuraminidase (NA) antigens
FluBlok	FluBlok	The University of Hong Kong	marketed	Recombinant protein vaccine	Influenza hemagglutinin (HA)
Licensed seasonal influenza vaccine	Licensed seasonal influenza vaccine	Novavax	marketed	Recombinant protein vaccine with adjuvant	Influenza hemagglutinin (HA) protein
Flublok™ Quadrivalent by Sanofi, Inc.	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein
Influsplit® Tetra	Influsplit® Tetra	ModernaTX, Inc.	phase 3	mRNA vaccine	Influenza hemagglutinin and neuraminidase antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

1. GlaxoSmithKline · 6 drugs in this class
2. Novavax · 5 drugs in this class
3. Vaxine Pty Ltd · 2 drugs in this class
4. D'Or Institute for Research and Education · 2 drugs in this class
5. Protein Sciences Corporation · 2 drugs in this class
6. Henogen · 1 drug in this class
7. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
9. National Vaccine and Serum Institute, China · 1 drug in this class
10. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class